Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

Section: Review articles

Running title: Derivative chromosome 9 deletions in CML

Brian J.P Huntly*, Anthony Bench and Anthony R. Green

Address for correspondence:
Professor A. R. Green
Department of Hematology,
University of Cambridge
Wellcome Trust/ MRC Building
Hills Road
Cambridge, CB2 2XY
United Kingdom
Tel: +44-1223-336820
Fax: +44-1223-762670
Email: arg1000@cam.ac.uk

Word counts: Abstract – 244 words
Text – 4752 words

* Current address- Department of Hematology, Brigham and Women’s Hospital, Harvard Institute of Medicine, Harvard Medical School, 4 Blackfan Circle, Room 418, Boston, MA 02115.

Grant Funding: BJPH is currently a Leukaemia Research Fund (UK) Senior Clinical Fellow and was previously funded by a Medical Research Council (UK) Clinical Training Fellowship. Work in the authors’ laboratories is funded by the Leukemia Research Fund and the Kay Kendall Leukemia Fund.
Abstract

Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10-15% of patients with CML. These deletions are large, span the translocation breakpoint and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions, exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than non-deleted patients following stem cell transplantation or treatment with Imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.
Introduction.

Chronic myeloid leukemia (CML) is a clonal hematological malignancy which arises in the stem cell compartment. Its molecular hallmark is the BCR-ABL fusion gene, which usually occurs as the result of the Philadelphia (Ph) translocation involving the long arms of chromosomes 9 and 22. The chimaeric BCR-ABL gene encodes a constitutively activated protein tyrosine kinase, which leads to the activation of multiple signaling pathways, with profound effects on cell cycle, adhesion and apoptosis. In murine transgenic and retroviral transduction models, expression of BCR-ABL has been shown to be both sufficient for initiation and necessary for maintenance of a leukemic phenotype.

The natural history of CML follows a biphasic pattern with an initial chronic phase, which is often asymptomatic. This is inevitably followed by progression of the disease through an ill-defined stage termed accelerated phase to the terminal blast crisis. During chronic phase, the myeloid compartment is expanded but the cells retain their capacity to differentiate and function normally, and drug treatment is usually effective. By contrast, blast crisis is characterized by loss of differentiation capacity together with refractoriness to therapy and is associated with the acquisition of new cytogenetic abnormalities in around 80% of patients. In some cases additional molecular abnormalities have been identified including mutations or deletions of p53, p16, or the RB1 protein, and mutation or overexpression of RAS or EVI-1. However in most cases the additional molecular lesions responsible for progression to blast crisis remain obscure.
Until recently first-line treatment for CML consisted of either allogeneic stem cell transplantation or an α-interferon–based regimen. However, both options are associated with considerable drawbacks. Although potentially curative stem cell transplantation is associated with considerable morbidity and mortality whilst α-interferon based regimens adequately control chronic phase disease but result in few long-term survivors. Recently, treatment with the protein tyrosine kinase inhibitor imatinib mesylate (Gleevec Glivec, formerly known as STI 571, Novartis, Basle, Switzerland) has resulted in excellent hematological and cytogenetic responses in all phases of CML. Comparison with historical controls shows improved survival in the later stages of the disease for patients treated with imatinib and it is hoped that the excellent response rates obtained in chronic phase patients will also translate into improved survival.

Two prognostic scoring systems are currently in use for patients with CML. The Sokal and Hasford/European scores are mathematical calculations derived from similar clinical and laboratory parameters measured at diagnosis. Both have limitations: the Sokal score is nearly 20 years old and was generated using patients treated with Busulphan or Hydroxyurea while the Hasford score was derived and validated using patients treated only with α-interferon. Neither scoring system is powerful enough to play a major role in guiding individual patient management decisions, a process that has become increasingly complex in the post-imatinib era. Robust prognostic indicators are
therefore badly needed to help clinicians and patients make informed management decisions.

Recently a number of groups have described deletions of the reciprocal product of the Ph translocation, the derivative chromosome 9, in a subset of patients with CML and have demonstrated that deletion status is a powerful prognostic indicator. This paper will review the discovery and clinical significance of detecting such deletions, their role in the pathogenesis of CML, the methods available for their detection and the significance of this paradigm for other malignancies associated with balanced translocations.

The anatomy of derivative chromosome 9 deletions in CML.

The discovery of derivative chromosome 9 deletions provides a good example of scientific serendipity. In the mid 1990s a number of groups were exploring the possibility of using fluorescence in-situ hybridization (FISH) to detect minimal residual disease in patients with CML by monitoring interphase nuclei in peripheral blood. The early probe systems relied solely on detecting co-localization of BCR and ABL probes (Figure 1, Panel A), but this approach was of little use for measuring residual disease since coincidental co-localization occurs in approximately 5% of normal interphase nuclei. To circumvent this problem, a number of new probe systems were designed which allowed
identification of the derivative chromosome 9 as well as the Ph chromosome \textsuperscript{39-41}(Figures 1, Panels B and C) and this strategy did indeed greatly reduce the number of false positive results \textsuperscript{39-41}.

However, the use of these new probe systems also resulted in an unexpected observation. Samples from some patients exhibited an abnormal signal pattern in which the BCR-ABL fusion signal on the Ph chromosome was accompanied by loss of the signals which should have marked the derivative chromosome 9 \textsuperscript{42 43 44} (Figures 1 and 2). The presence of a deletion was confirmed by microsatellite PCR and by using further locus specific probes for chromosome 9 and 22 sequences adjacent to the translocation breakpoints \textsuperscript{42, 44}(Figure 3). Although small deletions (approximately 10kb) of chromosome 22 sequences next to the translocation breakpoint had previously been demonstrated by Southern blotting, these were thought to be of no pathophysiological importance \textsuperscript{45 46 47}. By contrast the FISH data suggested the existence of substantial deletions spanning at least several hundred kilobases (Figure 3).

In order to delineate the size of the deletions FISH mapping was performed in the 16 patients with deletions originally described by Sinclair and colleagues \textsuperscript{44}. The results highlighted three main features of the deletions. Firstly, that the deletions were adjacent to and usually spanned the translocation breakpoint of the derivative chromosome 9. Secondly, the deletions were very large and in some instances involved several megabases of both chromosome 9 and 22 sequences. Thirdly, the size of the deletions varied considerably and there was no obvious clustering of centromeric or telomeric
deletion breakpoints (Figure 3). Large deletions of chromosome 22 sequences were identified independently by Grand and colleagues \(^{42}\) who demonstrated that a cosmid containing the \(hSNF/INI1\) gene, over a megabase telomeric to the chromosome 22 breakpoint, was deleted in 9/25 cases of CML in blast crisis and 5/21 cases in chronic phase. More recently, Storlazzi and colleagues have mapped deletions in a further 10 patients using an extensive panel of probes covering the chromosome 9 and 22 regions adjacent to the translocation breakpoints \(^{48}\). Their results identified deletions ranging from a few hundred kilobases to 8 megabases with variable centromeric and telomeric breakpoints, although the latter appeared to cluster in 2 regions in 7/10 patients.

**Deletions occur at the time of the Ph translocation in CML and therefore produce genetic heterogeneity *ab initio***.

Initial results raised the possibility that deletions were a relatively late event and reflected karyotypic instability associated with disease progression \(^{42}\). However, several lines of evidence have subsequently demonstrated that deletions occur at the time of the Ph translocation. Firstly distinct cohorts of patients analyzed in different phases of the disease were found to exhibit virtually identical frequencies of deletions \(^{49,50}\). Sequential paired samples have also been analyzed, with the first sample at diagnosis and the second sample taken following disease progression to blast crisis. No individual was found to acquire a deletion following disease progression despite the analysis of large numbers of metaphases \(^{49,50}\).
Secondly deletions were around three times more common in patients with variant Ph translocations when compared to patients with classical Ph translocations \(^{50, 51}\). More recently a study of 8 patients confirmed the relative frequency of deletions in patients with variant translocations and demonstrated loss of sequences from the third partner chromosome in those patients with deletion of chromosome 9 and/or 22 sequences \(^{52}\). Since the formation of variant translocations is thought to involve multiple double stranded DNA breaks \(^{53}\), these observations are consistent with a model in which each recombination event has a finite probability of inaccurate repair resulting in a deletion adjacent to the breakpoint.

Thirdly, if deletions occurred during disease progression it should be possible to identify cells carrying the Ph translocation but no deletion. However, several groups have analyzed large numbers of metaphases from patients who carried deletions, and have reported that every metaphase contained both a Ph translocation and a derivative chromosome 9 deletion \(^{48, 50, 49, 51}\).

Taken together these data demonstrate that, in a subset of patients, the recombination event which generates an apparently reciprocal translocation can also produce large genomic deletions. Since the Ph translocation is thought to initiate chronic phase CML \(^{1-3}\) these results point to the existence of previously unsuspected genetic heterogeneity in a proportion of patients with CML from the very beginning of their disease, an observation
with potential relevance for other malignancies associated with balanced translocations and/or fusion genes.

**Prognostic significance of derivative chromosome 9 deletions in CML.**

Sinclair and colleagues first noted that deletions of the derivative chromosome 9 were associated with a worse survival. Although deletion status did not appear to correlate with clinical features or laboratory results at diagnosis, 16 patients with deletions had a significantly shorter survival than 39 patients lacking deletions (p=0.006). Two subsequent large studies have confirmed the poor prognostic value of deletion status. In a study of 241 patients (39 with deletions and 202 without), Huntly and colleagues found the median survival of patients with deletions to be roughly half that of patients who did not carry deletions (median survival 38 months versus 88 months respectively, p = 0.0001). This finding was corroborated by Kolomeitz and colleagues, who compared the survival of 186 patients (23 with deletions and 163 without) and found a similar median survival difference (36 vs 84 months respectively, p = 0.005). In both of these patient cohorts (and BH, unpublished data) and in another two smaller studies, shorter survival reflected a shorter duration of chronic phase, with earlier disease progression.

The higher incidence of deletions in patients with variant Ph translocations may also provide an explanation for previous conflicting reports of the prognostic significance of
variant Ph translocations. In some series patients with a variant Ph translocation have been reported to have a worse prognosis compared to patients with a classical Ph translocation \(^{54, 55}\), while in other studies no difference has been found \(^{56, 57}\). However, the relative survival of patients with variant or classical Ph translocations will depend upon the proportions of patients with a deletion in the two groups. Consistent with this concept, there was no difference in the survival of patients with variant or classical Ph translocations when patients with deletions were removed from the analysis \(^{50}\).

It is important to know whether deletion status remains a useful prognostic indicator for patients receiving different treatment modalities. Early studies of the clinical significance of derivative chromosome 9 deletions included a mixture of patients treated with hydroxyurea or interferon-based regimens \(^{44, 50, 51}\). Deletion status remained a powerful predictor of response rate, duration of chronic phase and overall survival when analysis was limited to patients treated with interferon alone \(^{48-50}\). The significance of deletion status in the context of an allograft is largely unknown. In one relatively small series (12 patients with deletions and 58 without) there was an increased rate of relapse in patients with deletions following allogeneic transplantation \(^{51}\). These results suggest that allogeneic transplantation may be less effective in achieving disease eradication in patients with deletions of the derivative chromosome 9.

Data concerning deletion status in patients receiving imatinib are also preliminary. In a series of 397 patients (275 chronic phase, 54 accelerated phase and 68 blast crisis) who were treated with imatinib, survival of all patients was improved relative to historical
controls and, with a median follow up of 48 months, no significant survival difference was yet apparent (Huntly et al manuscript submitted). However, it should be noted that both hematological and cytogenetic responses were uniformly lower in chronic phase and more advanced phase patients with deletions, with these differences reaching statistical significance for hematological (89% vs 97%, patients with a deletion vs those without p = 0.04) and major cytogenetic responses (55% vs 75%, p = 0.008) in chronic phase and for hematological response (46% vs 82%, patients with a deletion vs those without p = 0.007) in more advanced phases. Progression free survival following initiation of imatinib was also significantly shorter for patients with deletions, treated either in chronic phase (p = 0.02) or advanced phases of the disease (p = 0.02). These data indicate that deletion status may retain prognostic significance in patients treated with imatinib but confirmation will require longer follow up.

A number of novel therapies are currently showing promise in preclinical models and phase I clinical trials. These include inhibitors of signal transduction pathways further downstream of BCR-ABL, such as farnesyl transferase inhibitors (which inhibit ras) \(^{58,59}\) and Phosphatidylinositol 3-kinase (PI3-kinase) inhibitors \(^{60,61}\), agents which decrease intracellular levels of BCR-ABL, such as the BCR-ABL molecular chaperone heat shock protein 90 inhibitor AAG (17-allyaminogeldanamycin), and other agents such as homoharringtonine \(^{62,63}\), decitabine \(^{64,65}\) and troxatyl \(^{66}\). Should the initial promise of these therapeutic agents be borne out, the design of randomized trials should include stratification for deletion status.
Deletion status appears to be both more powerful than, and independent of, the Sokal and Hasford scoring systems. A direct comparison of prognostic significance between deletion status, Sokal and Hasford score was possible in 210 patients in the series of Huntly and coworkers. As shown in Table 1 deletion status was a stronger prognostic indicator than either Sokal or Hasford score. Interestingly, patients with deletions are not merely a subset of those deemed high-risk by the Sokal and Hasford scoring systems, since similar numbers of patients with deletions were found in the Sokal and Hasford low-, intermediate- and high-risk groups (Table 2). Moreover, the Sokal and Hasford scoring systems retained prognostic significance if analysis was restricted to patients without a deletion. Taken together these observations suggest that deletion status and the two clinical scoring systems represent independent prognostic variables. The relative prognostic power of deletion status may reflect the fact that it directly detects a molecular event with a critical role in the progression of CML.

A reduction in telomere length has been described in a number of human cancers including CML and recent reports have suggested that telomere length may provide a prognostic indicator in patients with chronic phase CML. Iwoma and colleagues studied 32 patients treated with interferon and reported that patients with longer telomeres had improved cytogenetic responses, progression free and overall survival. However when analysis was extended to include a further 12 patients receiving other treatments no significant differences were obtained for any of these outcomes. More recently Brummendorf and coworkers reported that samples taken more than 2 years before disease evolution displayed longer telomere length than those taken less than 2
years before disease evolution. However, this study was able to assess only a total of 22 patients. Lastly Boulton and coworkers \(^{71}\) studied 59 patients and showed that telomere length was correlated with reduced time from diagnosis to accelerated phase but not with time to blast crisis or overall survival. These are small studies and require corroboration using larger cohorts of patients, but taken together they raise the possibility that assessment of telomere length may provide a useful additional prognostic marker. If this concept is confirmed it will be important to see whether there is any relationship between deletion status and telomere length.

**Derivative chromosome 9 deletions in acute lymphoblastic leukemia (ALL)**

The *BCR-ABL* gene rearrangement not only accompanies all cases of CML, but also occurs in around 25\% of adult and around 5\% of childhood acute lymphoblastic leukemia (ALL) \(^{72}\). However, these two diseases are clinically distinct and are associated with different patterns of *BCR-ABL* rearrangement. Ph-positive ALL also lacks the chronic phase of CML and is a clinically aggressive disease with a poor prognosis, particularly in adults. Almost all cases of CML, but only one-third of patients with ALL have an M-bcr breakpoint which results in fusion of the majority of the *c-ABL* oncogene to the first 13 or 14 exons of the *BCR* gene and gives rise to the p210 BCR-ABL protein \(^{73}\). By contrast, in approximately two-thirds of ALL patients the breakpoint within BCR is more proximal, between exons 1 and 2 of the BCR gene (m-bcr breakpoint), giving rise to a smaller p190 BCR-ABL protein.
Reid and colleagues investigated the possibility that the poor prognosis of Ph positive ALL may correlate with deletion status \(^{74}\). However, of 67 patients with Ph positive ALL studied, only a single case was found to carry a deletion detectable by FISH. Interestingly this patient had an m-bcr rearrangement, demonstrating that deletions are not restricted to patients with an M-bcr breakpoint. These results show that deletions occur less frequently in Ph-positive ALL than in CML and there are a number of possible explanations for this difference. Firstly, deletions are approximately 3 times more common in variant Ph translocations than in classical Ph translocations, and the former are rare in ALL (1-3% in ALL compared with 5-10% in CML) \(^{15,75-77}\). A second and related possibility is that some features of the M-bcr region may render it inherently more likely to be repaired inaccurately following rearrangement. The lower incidence of deletions in ALL would then reflect the relative infrequency of M-bcr rearrangements in this disease. Thirdly, deletion frequency may vary depending upon the target cell in which the Ph translocation occurs. CML results from the transformation of a multipotent hemopoietic stem cell \(^{1-3}\), whereas ALL is thought to result from transformation of a committed B-cell progenitor \(^{78}\). Lymphoid cells undergo antigen receptor rearrangements that require accurate joining of double stranded DNA breaks and may therefore employ more stringent mechanisms to minimize the occurrence of inaccurate repair.

**Molecular basis for the poor prognosis associated with deletions.**
A number of molecular mechanisms could conceivably be responsible for the poor prognosis associated with derivative chromosome 9 deletions. Deletions can result in formation of a fusion gene \(^{79}\) but this mechanism seems implausible given the considerable breakpoint heterogeneity on both centromeric and telomeric sides of the derivative chromosome 9 deletions \(^{44, 48}\) (Figure 3). However four other mechanisms warrant close inspection.

**Loss of ABL-BCR expression.**

Several groups have now shown that all patients with a deletion detectable by FISH lack expression of the ABL-BCR transcript \(^{80-82}\). However 65% of patients lacking ABL-BCR expression do not have a deletion detectable by FISH \(^{80}\). This observation suggests the existence of other mechanisms by which ABL-BCR transcription can be abolished. It is likely that small deletions occur that would abolish ABL-BCR transcription but that would be below the threshold of detection for the dual-fusion FISH and other, similar FISH-based techniques that use large probes. This would be consistent with previous evidence for small deletions adjacent to the translocation breakpoints in CML and other leukemias \(^{45, 46, 83-86}\). In addition, approximately 10% of patients have a breakpoint on the derivative chromosome 9 that is upstream of ABL exon 1b, and that therefore removes both sites at which ABL transcription is normally initiated \(^{83, 87}\). Finally some patients with a variant Ph translocation have 5' ABL and 3' BCR sequences present on separate chromosomes, suggesting that an ABL-BCR transcript would not be formed \(^{88}\)
Direct comparison of ABL-BCR expression with clinical outcome has shown that loss of ABL-BCR transcription is not associated with reduced survival or reduced length of chronic phase \(^{80,82}\). This demonstrates that lack of ABL-BCR expression is not sufficient for the poor prognosis associated with an overt chromosome 9 deletion. However, these results do not exclude the possibility that lack of ABL-BCR expression may be necessary for deletions to confer a poor outcome. It is conceivable that the ABL-BCR protein could directly or indirectly modulate activity of the BCR-ABL protein, a situation described for the reciprocal fusion protein in murine models of APML \(^{89,90}\). However, existence of a stable ABL-BCR protein product has not yet been demonstrated \(^{91,92}\).

**BCR-ABL transcript levels.**

Aberrant translocations which generate deletions on the derivative chromosome 9 may also result in the formation of small intronic deletions on the Ph chromosome. Such deletions would need to be small enough to permit formation of a BCR-ABL transcript but could nonetheless remove regulatory elements and thereby modulate BCR-ABL transcription. Several lines of evidence suggest that the level of BCR-ABL tyrosine kinase activity is important in determining the phenotype of BCR-ABL positive leukemias. An extra Ph chromosome is the most common secondary change seen with development of blast crisis in CML \(^{15}\); the p190 BCR-ABL tyrosine kinase associated with acute lymphoblastic leukemia (ALL) has increased kinase activity when compared to the standard CML p210 protein \(^{93}\); in murine cell lines BCR-ABL mediates cytokine independence and protection against apoptosis in a dose dependent manner \(^{94}\); and an
increase in p210 BCR-ABL expression precedes progression to accelerated phase or blast crisis in CML patients. To investigate this potential mechanism, BCR-ABL transcript levels were measured by real-time quantitative RT-PCR in patients with and without deletions. BCR-ABL transcript levels were not discernibly different between the two groups. Although the number of patients studied was small, these results argue that deletions are not associated with poor outcome as a consequence of altered BCR-ABL expression.

Deletions may represent a consequence of underlying genetic instability. Deletions may be associated with poor outcome because they represent a consequence of pre-existing genetic instability present within the target cell at the time of the Ph translocation. In this scenario poor prognosis would not be caused by the deletions but instead would reflect an underlying predisposition to accumulate additional genetic alterations. The fact that deletions occur in a subset of patients could represent heterogeneity within the stem cell compartment and/or differences among individuals.

This is a difficult mechanism to exclude with confidence. Patients with chronic phase CML do not exhibit genomic instability as assessed by microsatellite analysis but it is not clear whether patients with deletions were included in these studies and in any case these studies do not exclude other levels of genetic instability. Since deletions involve double stranded breaks, any predisposition to such events might be predicted to result in increased chromosomal rearrangements and yet patients with and without deletions
exhibit no difference in the number or type of chromosome rearrangements at diagnosis or at blast crisis. However blast crisis may be associated with reaching a threshold of genomic damage, and the number of chromosomal rearrangements present at blast crisis may be similar whatever route is taken to reach that threshold level. Current data therefore do not rigorously exclude the possibility that pre-existing genomic instability gives rise to both an increased probability of derivative chromosome 9 deletions and more rapid disease progression. Interestingly, the presence of genomic instability in a minority of patients prior to the Ph translocation would be consistent with recent reports of chromosome abnormalities in Ph negative cells in a small number of patients treated with imatinib.

Loss of a tumor suppressor gene

Notwithstanding the above caveats, loss of one or more genes important for disease evolution represents the most likely mechanism to explain the poor prognosis associated with deletions of the derivative chromosome 9. A model for the role of deletions in the progression of CML is shown in Figure 5. It is assumed that CML patients without a deletion develop blast crisis once the malignant clone has accumulated sufficient additional mutations. The model proposes that patients with a deletion have a head start in this process as a consequence of losing a critical gene or genes at the time of the Ph translocation. The molecular lesion associated with deletions may also cooperate with the BCR-ABL oncoprotein to accelerate genomic instability with patients carrying deletions therefore progressing more rapidly to blast crisis.
The biological consequences of deletion could be a direct effect of haploinsufficiency or a consequence of one or more “second hits” affecting the remaining normal alleles. The deletions are large extending up to 8 megabases on the chromosome 9 side of the translocation breakpoint, and up to 17 megabases on the chromosome 22 side. Existing data do not allow us to ascertain whether the critical area involves chromosome 9 sequences, chromosome 22 sequences, or both. Each of these regions are gene rich and between them contain at least 300 genes.

Mapping the likely location of critical genes will be more difficult than in the case of other deletions that are not associated with a translocation. In these other situations the presence of a clone of cells carrying a deletion implies that there is selection for such cells, and that in each patient their deletion is exerting a biological effect, presumably as a result of gene loss. By contrast, cells carrying the derivative chromosome 9 deletions will have a growth and/or survival advantage as a consequence of the concomitant Ph translocation. As a result it cannot therefore be assumed that all patients with a deletion will have lost a critical target gene(s). It will be important to take this issue into account when designing strategies for identification of critical target genes.

Methods for detecting deletions.

Three commercial FISH probe systems are currently available (Figure 6). The major difference between the three systems is the 3’ extent of the BCR probe. The ES probe (Vysis, Downers Grove, Illinois) does not extend beyond the M-bcr region and therefore
will not detect loss of chromosome 22 sequences from the derivative chromosome 9. By contrast loss of such sequences will be detected by the D-FISH (Q-biogene, Carlsbad, CA) and dual color/dual fusion probes (Vysis, Downers Grove, Illinois)(Figure 6).

Different probe systems therefore detect distinct classes of deletion and this is an important point to remember when using deletion status as a prognostic indicator. The ES probe system will not detect patients who have a deletion which only involves chromosome 22 sequences from the derivative chromosome 9, a situation thought to occur in approximately 5% of patients with deletions. Similarly by increasing the size of the BCR probe, the dual color/dual fusion system provides more robust detection of most such deletions. However, the BCR probe contig may now extend beyond the telomeric end of small deletions downstream of BCR and such small deletions would no longer be detected. It is not yet known whether patients with small deletions have the same prognosis as those with larger deletions, and this is likely to depend upon the precise location of one or more critical genes. However, it is important to emphasize that different methodologies vary in their ability to detect distinct subtypes of deletion and that different sizes of deletion may have distinct prognostic implications.

In addition to FISH a number of other techniques can be helpful. Microsatellite PCR will detect deletions but requires a comparison between tumor DNA (usually granulocytes or bone marrow mononuclear cells) and constitutional DNA (usually T-cells or buccal cells). RT-PCR for ABL-BCR can also be useful since the presence of a deletion and ABL-BCR expression are mutually exclusive (Table 3). It is therefore possible to restrict
FISH analysis to the 30-40% of patients who are ABL-BCR negative, a strategy that significantly reduces the number of patients in whom FISH is required.

A paradigm for other tumours associated with reciprocal chromosomal translocations?

Deletions of a few kilobases at translocation breakpoints have been demonstrated previously in other hematological malignancies but, as with Ph associated deletions, these were thought unlikely to be of any pathological significance 84-86, 100-106. The demonstration of unexpected large deletions in CML has prompted a number of FISH studies of other chromosomal translocations 51, 107, 108 (Table 4). Deletions have been described in association with a number of these translocations, with an incidence of between 2 and 16 percent. No detailed mapping is available, but as the probes used are comparable in size to the BCR and ABL probes, these deletions must be minimally hundreds of kilobases in size. These deletions further demonstrate previously unsuspected genetic heterogeneity in association with a number of chromosomal translocations. Little data currently exist about the prognostic significance of deletions associated with other translocations. However, in one small series of 20 AML patients with inv (16), who would normally have been considered to have good risk disease, both patients with associated 3' CBFB deletions exhibited refractory disease 51.

Several lines of evidence suggest that balanced translocations may be genetically complex. Differences in the precise genomic breakpoint can produce biologically distinct
protein products as seen with the p190, p210 and p230 BCR-ABL proteins\textsuperscript{73, 109, 110}. Alternative splicing can result in a single fusion producing more than one protein\textsuperscript{73}. Moreover, the product(s) of the reciprocal fusion gene may also contribute to the biology of some leukemias\textsuperscript{89, 90}. The story of derivative chromosome 9 deletions in CML further emphasizes that the consequence of an apparently simple translocation may be both varied and complex.
Acknowledgements.

The authors are grateful to past and present members of their labs for helpful discussions and particularly Cath Andrews, Soheila Swanton, Paul Sinclair, Alistair Reid and Ellie Nacheva for their cytogenetic expertise and to all the clinicians and cytogenetists who have generously provided us with samples and clinical data.
References


51. Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive
submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97:3581-3588.


**Tables and legends**

<table>
<thead>
<tr>
<th>Prognostic factor</th>
<th>High risk</th>
<th>Non High–risk</th>
<th>Survival difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% of patients</td>
<td>Median survival (95% CI)</td>
<td>% of patients</td>
</tr>
<tr>
<td>Deletion status</td>
<td>15</td>
<td>37 (25-49)</td>
<td>85</td>
</tr>
<tr>
<td>Sokal</td>
<td>37</td>
<td>56 (40-72)</td>
<td>63</td>
</tr>
<tr>
<td>Hasford</td>
<td>22</td>
<td>55 (34-76)</td>
<td>78</td>
</tr>
</tbody>
</table>

**Table 1 – Deletion status is a more powerful prognostic indicator than either the Sokal or Hasford clinical scores.** Non high-risk refers to patients lacking a derivative chromosome 9 deletion or, in the Sokal and Hasford systems, the combined low and intermediate–risk groups. High-risk refers to patients with a deletion or to Sokal and Hasford high–risk groups. Comparison of survival was made by log-rank analysis with the p values shown. Data from Huntly et al.⁵⁰

<table>
<thead>
<tr>
<th>% of patients with deletions</th>
<th>Sokal</th>
<th>Hasford</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>14%</td>
<td>13%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>13%</td>
<td>18%</td>
</tr>
<tr>
<td>High</td>
<td>18%</td>
<td>15%</td>
</tr>
</tbody>
</table>

**Table 2 – Deletion status is independent of Sokal or Hasford score.** Numbers represent the percentage of patients with a derivative chromosome 9 deletion in each risk category. Data from Huntly et al.⁵⁰
**Table 3** – The presence of a deletion and *ABL-BCR* expression are mutually exclusive. Numbers represent percentages of deleted and non-deleted patients. All patients with a deletion lack *ABL-BCR* expression and also all patients who express *ABL-BCR* are non-deleted. Data from Huntly et al. 80.

<table>
<thead>
<tr>
<th>Deletion status</th>
<th>ABL-BCR expression (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td>Deleted</td>
<td>35</td>
</tr>
<tr>
<td>Non-deleted</td>
<td>65</td>
</tr>
</tbody>
</table>

**Table 4**– Other haematological malignancies associated with chromosomal translocations in which large deletions have been demonstrated by FISH. The translocation, fusion partners, associated haematological malignancy and reference are shown in the appropriate columns. The published incidence of deletions, from FISH studies is also shown. ALL, acute lymphoblastic leukemia, AML, acute myeloid leukemia, AL, acute leukemia.

<table>
<thead>
<tr>
<th>Translocation</th>
<th>Fusion partners</th>
<th>Associated hematological malignancy</th>
<th>Incidence (%)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(9;22)</td>
<td><em>BCR-ABL</em></td>
<td>ALL</td>
<td>2/80 (2)</td>
<td>74, 51</td>
</tr>
<tr>
<td>inv (16)</td>
<td><em>CBFβ-MYH11</em></td>
<td>AML</td>
<td>2/20 (10)</td>
<td>51</td>
</tr>
<tr>
<td>t(8;21)</td>
<td><em>AML1-ETO</em></td>
<td>AML</td>
<td>6/79 (8)</td>
<td>51, 108</td>
</tr>
<tr>
<td>11q23</td>
<td><em>MLL</em> + multiple partners</td>
<td>AL</td>
<td>9/58 (16)</td>
<td>51, 107</td>
</tr>
</tbody>
</table>
Figures and legends

A Early probe systems

B Triple probe system

C Dual fusion probe system

ABL  BC  ASS

Figure 1
Figure 1- FISH systems for detection of the Ph translocation and derivative chromosome 9 deletions.
In each case an ideogram and an interphase nucleus are shown for a normal cell, a cell carrying the Ph translocation alone (Ph positive) and a Ph positive cell carrying a derivative chromosome 9 deletion (Ph positive with der 9 deletion)

**Panel A - Early probe system.** The ABL (red) and BCR (green) loci are labeled with different colored fluorochromes. No difference in the metaphase or interphase patterns is seen between patients who carry a deletion and those who do not.

**Panel B - Triple probe system.** In addition to the ABL and BCR loci a third probe containing the ASS gene is labeled in blue. With this system, the translocation again produces a fusion of the BCR and ABL probes on the Ph chromosome but also marks the derivative chromosome 9 with a single blue signal. This signal is missing in patients with deletions.

**Panel C - Dual fusion probe system.** The ABL and BCR loci are again labeled with different colored fluorochromes. However in these probe systems the probe size is larger and spans the translocation breakpoints. Both these probes hybridize to the Ph chromosome and also to the derivative chromosome 9 creating two fusion signals in a Ph positive patient who lacks a deletion but only one fusion signal in a Ph positive patient with a derivative chromosome 9 deletion. In addition this system can differentiate between loss of chromosome 9 sequences only, chromosome 22 sequences only or both from the derivative chromosome 9.
Figure 2 – Demonstration of derivative chromosome 9 deletions by a dual fusion probe system.

Metaphase images are shown using a dual fusion system (dual color, dual fusion probe system, Vysis) in a patient without a derivative chromosome 9 deletion (panel A) and in patients with a deletion (panels B-D). The ABL (red) and BCR (green) signals mark the normal 9 and 22 chromosomes, respectively, and the Philadelphia (Ph) chromosome is marked by a fusion signal. In patients without a deletion, the dual color, dual fusion system also labels the derivative chromosome 9 with a fusion signal (panel A). This fusion signal is missing from the derivative chromosome 9 in patients who carry a deletion of both chromosome 9 and 22 sequences (panel B). This probe system is also able to detect those patients in whom only chromosome 9 sequences (panel C) or chromosome 22 sequences (panel D) are deleted.
Figure 3 - Derivative chromosome 9 deletions are large, span the translocation breakpoint and demonstrate heterogeneous deletion breakpoints. A summary of FISH mapping of 16 patients with deletions is shown. Locus-specific probes from 9q34 and 22q12 together with corresponding physical and genomic map data are shown. White boxes indicate the retention of a locus; black boxes indicate the loss of a locus and grey boxes indicate not performed. (Adapted from Sinclair et al 39).
Fig 4 - The presence of derivative chromosome 9 deletions shortens length of chronic phase and survival. Two Kaplan Meier graphs are shown for a cohort of 241 patients with duration of chronic phase and survival compared according to deletion status. Log-rank analysis demonstrates significantly shorter duration of chronic phase and overall survival for those patients who carry deletions (median follow-up was similar for both groups at 31 months for patients who carried deletions and 34 months for those without a deletion). Data shown from Huntly et al. and unpublished observation (B Huntly, 2002).
Figure 5 - Model for the role of deletions of the derivative chromosome 9 in the progression of CML.

In patients without deletions, the \textit{BCR-ABL} gene rearrangement and resultant expression of BCR-ABL protein initiates the chronic phase of the disease. Blast crisis develops with the accumulation of further mutations. However, in the subset of patients with deletions, the recombination event not only produces the translocation but also a deletion (black bar) with the resultant loss of one or more tumor suppressor genes (TSG) from the derivative chromosome 9. The time to blast crisis is therefore reduced since fewer additional mutations are required.
**Figure 6 - Commercially available FISH probe systems for the detection of derivative chromosome 9 deletions.** Structure of the ABL and BCR loci showing the common breakpoints (arrows) and the probes used in the commercially available probe systems: the extra signal (ES), D-FISH and dual color, dual fusion detection system (see text).

ASS, Arginine succinate synthetase; Met 8604, Met 8604 gene; IGLV, Immunoglobulin Lambda light chain locus.
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia

Brian J P Huntly, Anthony Bench and Anthony R Green